379 related articles for article (PubMed ID: 16585609)
1. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N; Rea D; Tieng V; Dulphy N; Brun M; Cayuela JM; Rousselot P; Tamouza R; Le Bouteiller P; Mahon FX; Steinle A; Charron D; Dombret H; Toubert A
J Immunol; 2006 Apr; 176(8):5108-16. PubMed ID: 16585609
[TBL] [Abstract][Full Text] [Related]
2. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
[TBL] [Abstract][Full Text] [Related]
3. The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J; Hilpert J; Placke T; Grünebach F; Steinle A; Salih HR; Krusch M
Int J Cancer; 2010 Nov; 127(9):2119-28. PubMed ID: 20143399
[TBL] [Abstract][Full Text] [Related]
4. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
5. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C
Leukemia; 2012 Mar; 26(3):465-74. PubMed ID: 21904381
[TBL] [Abstract][Full Text] [Related]
6. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions.
Sconocchia G; Lau M; Provenzano M; Rezvani K; Wongsena W; Fujiwara H; Hensel N; Melenhorst J; Li J; Ferrone S; Barrett AJ
Blood; 2005 Nov; 106(10):3666-72. PubMed ID: 16046526
[TBL] [Abstract][Full Text] [Related]
7. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.
Zhang QY; Mao JH; Liu P; Huang QH; Lu J; Xie YY; Weng L; Zhang Y; Chen Q; Chen SJ; Chen Z
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3378-83. PubMed ID: 19208803
[TBL] [Abstract][Full Text] [Related]
8. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Parmar S; Smith J; Sassano A; Uddin S; Katsoulidis E; Majchrzak B; Kambhampati S; Eklund EA; Tallman MS; Fish EN; Platanias LC
Blood; 2005 Oct; 106(7):2436-43. PubMed ID: 15790787
[TBL] [Abstract][Full Text] [Related]
10. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
11. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Zhang JH; He YL; Zhu R; Du W; Xiao JH
Tumour Biol; 2017 Jun; 39(6):1010428317713394. PubMed ID: 28639894
[TBL] [Abstract][Full Text] [Related]
12. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
13. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Sheng Z; Ma L; Sun JE; Zhu LJ; Green MR
Blood; 2011 Sep; 118(10):2840-8. PubMed ID: 21715304
[TBL] [Abstract][Full Text] [Related]
15. Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Ernst T; Hoffmann J; Erben P; Hehlmann R; Hochhaus A; Müller MC
Clin Chem Lab Med; 2008; 46(3):318-22. PubMed ID: 18303987
[TBL] [Abstract][Full Text] [Related]
16. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
[TBL] [Abstract][Full Text] [Related]
18. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
[TBL] [Abstract][Full Text] [Related]
19. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Kim JH; Chu SC; Gramlich JL; Pride YB; Babendreier E; Chauhan D; Salgia R; Podar K; Griffin JD; Sattler M
Blood; 2005 Feb; 105(4):1717-23. PubMed ID: 15486067
[TBL] [Abstract][Full Text] [Related]
20. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
